Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
4D Molecular Therapeutics, Inc. (FDMT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration • Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial in July, nearly two quarters ahead of initially projected enrollment completion • Presented positive interim data from aerosolized 4D-710 Phase 1/2 AEROW clinical trial for patients with cystic fibrosis lung disease • Anticipate multiple clinical data and regulatory interaction updates onlead clinical-stage product candidates 4D-150 in wet AMD and 4D-710 in cystic fibrosis lung disease over the next 12 mo..."
05/10/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights • Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration at the 2023 ARVO Annual Meeting • On track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3 2023 • Acquired all worldwide rights to short-form human complement factor H from Aevitas Therapeutics, Inc. and announced sCFH as payload for 4D-175 lead product candidate for geographic atrophy • Multiple additional clinical data updates on clinical-stage product candidates expected later in 2023, including on 4D-710 for cystic fibrosis lung disease in Q2 2023 • Closed upsized public offer..."
03/15/2023 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights • Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration and diabetic macular edema , 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy • Demonstrated robust clinical gene delivery, tolerability and initial biological activity with first three customized and evolved vectors generated from Therapeutic Vector Evolution platform • Expanded preclinical pipeline with large market geographic atrophy and alpha-1 antitrypsin deficiency lung disease programs • On track for multiple clinical data updates on lead clinical-stage product candidates during 2023 • Cash, cash equivalents and marketable ..."
11/09/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights"
08/12/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy